Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
31 Juillet 2024 - 2:00PM
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical
company developing innovative therapies for patients with rare
cardiopulmonary disease, announced today that it will report its
second quarter 2024 financial results on August 7, 2024. The
company will host a live webcast at 8:30 a.m. Eastern
Time to discuss financial results and provide a corporate
update.
The live webcast will be available
on Liquidia's website
at https://liquidia.com/investors/events-and-presentations. A
rebroadcast of the event will be available and archived for a
period of one year at the same location.About Liquidia
CorporationLiquidia Corporation is a
biopharmaceutical company developing innovative therapies for
patients with rare cardiopulmonary disease. The company’s current
focus spans the development and commercialization of products in
pulmonary hypertension and other applications of its proprietary
PRINT® Technology. PRINT enabled the creation of Liquidia’s
lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an
investigational drug for the treatment of pulmonary arterial
hypertension (PAH) and pulmonary hypertension associated with
interstitial lung disease (PH-ILD). The company is also developing
L606, an investigational sustained-release formulation of
treprostinil administered twice-daily with a next-generation
nebulizer, and currently markets generic Treprostinil Injection for
the treatment of PAH. To learn more about Liquidia, please
visit www.liquidia.com.
Contact
InformationInvestors:Jason AdairChief
Business Officer919.328.4350jason.adair@liquidia.com
Media: Patrick WallaceDirector, Corporate
Communications919.328.4383patrick.wallace@liquidia.com
Liquidia (NASDAQ:LQDA)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Liquidia (NASDAQ:LQDA)
Graphique Historique de l'Action
De Août 2023 à Août 2024